COMPANY:

Caris Life Sci

"Caris Life Sciences®...announced...that the University of Chicago (UChicago) Medicine Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences^®(Caris)...announced a strategic research partnership with Incyte Corporation...to augment precision medicine approaches for Incyte's oncology pipeline....Under the terms of the agreement, Incyte will leverage Caris' data insights and analytics capabilities to discover novel biomarkers and optimize clinical positioning strategies for its oncology programs. For drug candidates developed under the collaboration, patients enrolled in Incyte-led clinical trials will undergo longitudinal testing with Caris' comprehensive tissue and liquid molecular profiling assays. Incyte will also leverage Caris' biomarker-driven patient selection for clinical trials including options to partner on developing companion diagnostics for programs in the partnership."

"Caris Life Sciences^®...announced that the company and partners within the Caris Precision Oncology Alliance™ (POA) will collectively present five studies across three tumor types at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, February 16-18, 2023 in San Francisco (Tabletop #50)."

"Caris Life Sciences®...announced...that the UCI Health Chao Family Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences®...announced that the company and partners within the Caris Precision Oncology Alliance™ (POA) will collectively present 18 studies across more than six tumor types at the 2023 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, January 19-21, 2023 in San Francisco...large number of collaborative abstracts accepted for presentation at ASCO GI, demonstrating the power of Caris’ comprehensive molecular profiling and the large-scale collaboration between POA sites..."

"Singapore-based therapeutics developer Juniper Biologics said...that it has been granted distribution rights for Caris Life Sciences' molecular profiling services in Southeast Asia...Caris' comprehensive molecular profiling services include whole-exome and transcriptome sequencing to guide the use of molecularly targeted therapies."

"Caris Life Sciences^®...announced an expansion of their collaboration to research, develop and commercialize novel XmAb^® bispecific and multi-specific antibodies directed against novel targets, identified and proposed by Caris, for the treatment of patients with cancer. Building upon the initial August 2022 agreement, this expanded collaboration will increase the number of targets and cancer types that Caris will interrogate with its proprietary, multi-omics discovery engine platform, Caris Discovery....Under the terms of the new agreement, Xencor will receive exclusive worldwide rights to research, develop and commercialize products directed to up to three targets discovered under the collaboration. Caris will receive an upfront payment and will be eligible to receive up to $187 million in development and commercial milestone payments."

"This retrospective study aimed to use real-world data to determine the prevalence and clinical significance of estrogen receptor (ER) loss in invasive lobular carcinoma (ILC). Results demonstrate that, based on analysis of a large real-world dataset of over 20,000 patients with advanced breast cancer, ER-loss occurs in around one in ten ILC patients and has poor prognostic implications compared to ILC without ER loss or invasive ductal carcinoma with ER-loss. Genomic analysis also revealed significant differences between breast cancer patients with ER-loss who responded to treatment and those who did not."

"Caris Life Sciences...and Hummingbird Bioscience...today announced a strategic collaboration to advance clinical development of Hummingbird Bioscience's anti-HER3 therapy, HMBD-001....Leveraging Caris' extensive real-world clinico-genomic database to support clinical trial design, Hummingbird Bioscience will be better able to prospectively identify patients with molecular biomarkers that are potentially associated with response to HMBD-001."

"Caris Life Sciences® (Caris)...announced today that Cleveland Clinic Cancer Center has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative precision medicine focused research that improve the clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced...that University of Iowa Holden Comprehensive Cancer Center has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Everything Genetic said...that it will distribute Caris Life Sciences' Molecular Intelligence Tumor Seek service in the UK...Everything Genetic is based in Nantwich, an English city equidistant between Liverpool and Birmingham, and will be the sole distributor of Caris' MI Tumor Seek service in the UK."

"Caris Life Sciences® (Caris)...announced...that Virginia Commonwealth University (VCU) Massey Cancer Center (Massey) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research."

"Caris Life Sciences^®(Caris)...announced today that The University of Tennessee Medical Center's (UTMC) Cancer Institute has joined Caris' Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences®...announced...that St. Luke’s University Health Network (SLUHN) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research."

"Caris Life Sciences...announced today that Indiana University Melvin and Bren Simon Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"BriaCell Therapeutics Corp...announced that it has signed an agreement with Caris Life Sciences® (Caris)...Under the terms of the agreement, Caris will help BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial in advanced metastatic breast cancer of certain genetically defined subgroups...through Caris’ comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing), Caris will perform tumor profiling for the patients enrolled in the clinical trial."

"Caris Life Sciences® (Caris)...announced that the company and partners within its Precision Oncology Alliance™ will collectively present nine studies covering a diversity of tumor types and genomic alterations at the 2022 European Society for Medical Oncology (ESMO) Congress from September 9-13, 2022..."

"Caris Life Sciences® (Caris)...announced...that The Medical College of Wisconsin Cancer Center (MCWCC) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences®...announced...that OU Health Stephenson Cancer Center has joined the Caris Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences...announced today that Northside Hospital Cancer Institute (NHCI) has joined Caris' Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences...announced an enhanced partnership with Epic, a leader in software systems for electronic health records (EHR), to integrate Caris’ market leading molecular testing portfolio with Epic’s Orders and Results Anywhere (ORA) network."

"Caris Life Sciences...announced today that Miami Cancer Institute, part of Baptist Health South Florida, has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences®...introduced its Caris Assure™ liquid biopsy assay at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago (Booth #22081)...In an initial performance validation study of this first-of-its-kind whole exome, whole transcriptome (22,000 gene) blood assay, Caris Assure demonstrated more than 95 percent sensitivity for variant frequencies greater than 0.5 percent, while maintaining greater than 99.99 percent specificity."

"Caris Life Sciences®...the Prostate Cancer Clinical Trial Consortium (PCCTC) and Sorrento Therapeutics, Inc...announced a strategic collaboration to guide more precise treatment decisions for patients with advanced prostate cancer...Utilizing Caris’ unique MI Profile, PCCTC investigators will profile whole exome DNA, whole transcriptome RNA, and proteins from samples collected from participants enrolled in the trial, creating a molecular blueprint to better understand mechanisms of response and resistance following therapy."

"Caris Life Sciences...announced that the company and partners within its Precision Oncology Alliance™ (POA) will collectively present 45 studies across more than 20 various solid tumor types at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7, 2022 (Booth #22081)."

"Caris Life Sciences®...announced today that Loma Linda University Cancer Center (LLU Cancer Center) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced today that The University of Kentucky Markey Cancer Center (Markey) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

P=NA | N=9,212 | "The study found that tumor expression of genes related to drug exposure can predict outcomes after chemotherapy treatment: High EGR1 and FOS mRNA independently predict response to FOLFOX in patients with wild-type p53 tumors; Low CCNB1 mRNA correlates with good prognosis of CRC patients with tumors harboring TP53 loss of function mutations; Low expression of BTG2 predicts better prognosis in patients with MSI-High TP53 mutated tumors; Gene signatures may demonstrate enhanced predictive ability as compared to individual transcript effects."

"Zentalis Pharmaceuticals, Inc....announced a strategic collaboration with Caris Life Sciences, the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare. Through this partnership, Caris will sequence individuals’ complete exome and transcriptome, leverage real-world data to help inform clinical development and help identify eligible patients for Zentalis’ clinical trials. Initially, Caris will assist in the recruiting efforts for Zentalis’ clinical trials investigating the Wee1 inhibitor, ZN-c3....Under the terms of the agreement, Zentalis retains full ownership of its therapeutic candidates."

"Pyramid Biosciences, Inc., and Caris Life Sciences® (Caris), today announced a collaboration to enhance identification of potential patients with NTRK fusion-driven cancers for participation in the ongoing Phase 1/2 trial (PBI-200-101) of Pyramid's lead oncology program PBI-200, a best-in-class, next-generation, highly CNS-penetrant TRK inhibitor...Caris' tailored MI Trials offering helps match the right patients to the right biopharma trials based on both the individual patient's molecular tumor profile and the eligibility requirements of a given study."

"Caris Life Sciences® (Caris)...announced today that Tampa General Hospital Cancer Institute (TGH Cancer Institute) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences® (Caris)...announced today that the National Cancer Center (NCC) Japan has joined Caris’ Precision Oncology Alliance™ (POA)...As a member of the POA, NCC Japan will collaborate with Caris to utilize study data inclusive of patients of Japanese descent, which will add significant diversity in the patient populations being studied for impactful precision oncology research."

"Caris Life Sciences® (Caris)...announced today that the The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research."

"Caris Life Sciences®...and HotSpot Therapeutics, Inc...announced a strategic partnership to advance precision medicine approaches for HotSpot’s emerging product portfolio. The partnership will focus initially on two therapeutic programs, the first of which is HotSpot’s novel allosteric inhibitor of the E3 ubiquitin ligase CBL-B, an important target in cancer immunotherapy, spanning from pre-First in Human (FIH) trials through potential Companion Diagnostics (CDx) and launch."

"Caris Life Sciences...announced that it will present results at the San Antonio Breast Cancer Symposium (SABCS) that illustrate the potential impact of molecular profiling on the treatment of breast cancer...Relationships between breast cancer metastases site and mutations detected by DNA next-generation sequencing were investigated using 12,464 breast cancer samples using Caris’ Next-Generation Sequencing (NGS) technology. Results demonstrate that breast cancer metastases are different from primary tumors and have site-specific mutational profiles."

"Caris Life Sciences has been caught in the crossfire between the US Federal Trade Commission and Illumina, as they clash over Illumina's decision to acquire Grail...The requests are part of Illumina's defense strategy in the FTC administrative hearing challenging the Grail acquisition and relate to Caris' plans to develop a liquid biopsy multi-cancer early detection (MCED) test, including details of precisely how it is developing a competing product."

"Caris Life Sciences®...announced today that the Herbert Irving Comprehensive Cancer Center (HICCC) has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences®...announced today that the Georgia Cancer Center at Augusta University has joined Caris’ Precision Oncology Alliance™ (POA). The POA is a growing network of leading cancer centers across the globe that collaborate to advance precision oncology and biomarker-driven research. POA members work together to establish and optimize standards of care for molecular testing through innovative research focused on predictive and prognostic markers that improve the clinical outcomes for cancer patients."

"Caris Life Sciences®...and Ono Pharmaceutical Co., Ltd...announced a strategic collaboration to leverage Caris’ best-in-class molecular profiling, including its novel, liquid biopsy circulating nucleic acids sequencing (cNAS) assay, across several studies beginning later this year...Under the terms of the agreement, Caris will provide comprehensive molecular profiling analysis in support of several Ono clinical studies evaluating a range of targeted and immune-based therapies, including an initial phase III trial, and others to be named at a later date."

"Caris Life Sciences®...and ESSA Pharma Inc...announced today a Precision Development program to support ESSA's ongoing clinical development of EPI-7386, a first-in-class N-terminal domain androgen receptor inhibitor, in patients with metastatic castration-resistant prostate cancer ('mCRPC') failing current standard-of-care therapies. Under the terms of the agreement, Caris and ESSA will evaluate patient blood samples to assess genetic profiles utilizing Caris' Whole Transcriptome Sequencing (WTS) and Whole Exome Sequencing (WES) platform. ESSA will utilize these liquid biopsies, including longitudinal data from serial samples, to better characterize the tumor biological profiles of patients in the ongoing monotherapy clinical trial of EPI-7386 in mCRPC patients."

“Caris Life Sciences…announced results from a study highlighting a strong association between CCR5/CCL5 gene expression and distinct molecular features including Consensus Molecular Subtype, tumor mutational burden, lymphocyte infiltration in the tumor microenvironment, as well as patient outcome, and treatment benefit in Colorectal Cancer (CRC). These findings, being presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, demonstrate how comprehensive genomic profiling can help treating physicians better utilize targeted therapies to improve patient outcomes.”